Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries
暂无分享,去创建一个
L. Pagano | A. Simon | M. Vehreschild | V. Rickerts | M. Caira | A. Nosari | R. Herbrecht | D. Sheppard | C. Lass‐Flörl | A. Busca | J. Vehreschild | C. Girmenia | O. Cornely | A. Ullmann | S. Cesaro | Z. Ráčil | W. Heinz | C. Valentini | A. Candoni | L. Potenza | C. Gasbarrino
[1] C. Elie,et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] P. Hamal,et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[3] J. Perfect,et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. , 2011, The Journal of antimicrobial chemotherapy.
[4] K. Gupta,et al. Rhino-Orbital-Cerebral Zygomycosis in Solid Organ Transplant Recipients , 2010, Transplantation.
[5] B. Spellberg,et al. The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. , 2010, The Journal of antimicrobial chemotherapy.
[6] A. Simon,et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. , 2009, The Journal of antimicrobial chemotherapy.
[7] B. Spellberg,et al. Posaconazole Mono- or Combination Therapy for Treatment of Murine Zygomycosis , 2008, Antimicrobial Agents and Chemotherapy.
[8] J. Guarro,et al. Posaconazole Combined with Amphotericin B, an Effective Therapy for a Murine Disseminated Infection Caused by Rhizopus oryzae , 2008, Antimicrobial Agents and Chemotherapy.
[9] M. Dierich,et al. Posaconazole Enhances the Activity of Amphotericin B against Hyphae of Zygomycetes In Vitro , 2008, Antimicrobial Agents and Chemotherapy.
[10] M. Rinaldi,et al. In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents , 2007, Antimicrobial Agents and Chemotherapy.
[11] D. Loebenberg,et al. In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts , 2006, Antimicrobial Agents and Chemotherapy.
[12] D. Kontoyiannis,et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] A. Maniatis,et al. In vitro activities of combinations of amphotericin B, posaconazole and four other agents against Rhizopus , 2008 .